Trial to Assess the Ocular Safety of SCH 530348 in Patients With Atherosclerosis (Study P05183AM1)(COMPLETED)

This study has been completed.
The TIMI Study Group
Duke Clinical Research Institute
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp. Identifier:
First received: February 4, 2008
Last updated: September 26, 2013
Last verified: September 2013

This study is designed to evaluate the long-term ocular safety of SCH 530348 in subjects with established atherosclerotic disease who are enrolled into the TRA 2°P - TIMI 50 Study (P04737).

Condition Intervention Phase
Myocardial Infarction
Cerebrovascular Accident
Drug: SCH 530348
Drug: Placebo
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Ocular Safety of SCH 530348 in Subjects Participating in the Schering-Plough P04737 Study (TRA^SM-Secondary Prevention Ocular Safety Study)

Resource links provided by NLM:

Further study details as provided by Merck Sharp & Dohme Corp.:

Primary Outcome Measures:
  • Incidence of vacuolization in the INL of the retina through treatment and follow-up. Vacuolization is defined as the presence of more than one vacuole compared to baseline and will be evaluated by ocular coherence tomography (OCT). [ Time Frame: Through the end of study ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Decrease in visual acuity score of at least seven letters from baseline. All visual acuity testing will follow a standardized refraction. [ Time Frame: Through the end of study ] [ Designated as safety issue: Yes ]

Enrollment: 261
Study Start Date: July 2008
Study Completion Date: October 2010
Primary Completion Date: October 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: SCH 530348 Drug: SCH 530348
2.5-mg tablet daily for at least 1 year
Placebo Comparator: Placebo Drug: Placebo
matching tablet daily for at least 1 year


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Men and women at least 18 years old with evidence or a history of atherosclerosis involving the coronary, cerebral, or peripheral vascular systems

Exclusion Criteria:

  • The study will include subjects who meet none of the exclusion criteria for the parent protocol (P04737) and also the following:

    • history or evidence of age-related macular degeneration on baseline evaluation
    • history of diabetic macular edema, or evidence of treated diabetic retinopathy on baseline evaluation
    • history or evidence of other retinal diseases, including retinal injury, on baseline evaluation
    • history or evidence of retinal surgery, including laser photocoagulation, on baseline evaluation
    • history or evidence of glaucoma on baseline evaluation
    • history or evidence of high intraocular pressure of >22 mm Hg on baseline evaluation
    • evidence of center foveal thickness of >190 µm on baseline OCT examination
    • presence of vacuoles in the retina on baseline OCT
  Contacts and Locations
No Contacts or Locations Provided
  More Information

No publications provided

Responsible Party: Merck Sharp & Dohme Corp. Identifier: NCT00617123     History of Changes
Other Study ID Numbers: P05183
Study First Received: February 4, 2008
Last Updated: September 26, 2013
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Myocardial Infarction
Cerebral Infarction
Arterial Occlusive Diseases
Vascular Diseases
Cardiovascular Diseases
Pathologic Processes
Myocardial Ischemia
Heart Diseases
Brain Infarction
Brain Ischemia
Cerebrovascular Disorders
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases processed this record on April 16, 2014